28 January 2020 : Laboratory Research
Downregulated miR-524-5p Participates in the Tumor Microenvironment of Ameloblastoma by Targeting the Interleukin-33 (IL-33)/Suppression of Tumorigenicity 2 (ST2) Axis
Lijie Chen1A, Guannan Wang1B, Xue Qiao2C, Xiaobin Wang1D, Jinwen Liu1E, Xing Niu1F, Ming Zhong13AG*DOI: 10.12659/MSM.921863
Med Sci Monit 2020; 26:e921863
Abstract
BACKGROUND: Ameloblastoma (AB) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence. In this study, we hypothesized that miR-524-5p could be involved in the tumor microenvironment by targeting interleukin-33 (IL-33)/suppression of tumorigenicity 2 (ST2) in AB.
MATERIAL AND METHODS: The microRNA (miRNA) expression profile of AB tissues and normal oral mucosa tissues (NOM; 6 paired samples) was analyzed. The miRNAs with fold change ≥2 and P<0.05 were considered to be differentially expressed. Among them, downregulated miR-524-5p was verified by real-time qPCR. Potential targets of miR-524-5p were predicted by bioinformatics analysis. The expression levels of target genes were detected using real-time qPCR and Western blot, respectively. Immunohistochemistry analysis of target genes was performed, and we also assessed the correlation between miR-524-5p and its target.
RESULTS: Microarray analysis results first indicated miR-524-5p is a downregulated miRNA in AB tissues. Real-time qPCR results confirmed the expression pattern of miR-524-5p in AB tissues. Moreover, IL-33 and its receptor ST2 were significantly overexpressed. As shown in immunohistochemistry results, IL-33 was positively expressed in lymphocytes and plasma cells, suggesting that IL-33/ST2 participates in tumor immune responses in the tumor microenvironment. Correlation analysis suggested that miR-524-5p expression was negatively correlated with IL-33/ST2.
CONCLUSIONS: Our findings reveal that downregulated miR-524-5p can participate in the tumor microenvironment of AB by targeting the IL-33/ST2 axis.
Keywords: Ameloblastoma, tumor microenvironment, Down-Regulation, Interleukin-1 Receptor-Like 1 Protein, Interleukin-33
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical CancerMed Sci Monit In Press; DOI: 10.12659/MSM.945964
Clinical Research
Inflammatory Biomarkers in Smokers: Implications for Ligamentum Flavum HypertrophyMed Sci Monit In Press; DOI: 10.12659/MSM.947508
Clinical Research
Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal VeinMed Sci Monit In Press; DOI: 10.12659/MSM.947391
Review article
Regulatory Efforts and Health Implications of Energy Drink Consumption by Minors in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.947124
Most Viewed Current Articles
17 Jan 2024 : Review article 7,160,485
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,385
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,806
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 22,071
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912